Suppr超能文献

穿透性角膜移植术后青光眼治疗的升级

Escalation of glaucoma therapy after penetrating keratoplasty.

作者信息

Al-Mohaimeed Mansour, Al-Shahwan Sami, Al-Torbak Abdullah, Wagoner Michael D

机构信息

Department of Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

出版信息

Ophthalmology. 2007 Dec;114(12):2281-6. doi: 10.1016/j.ophtha.2007.08.043.

Abstract

PURPOSE

To determine the prevalence and risk factors for escalation of glaucoma therapy after penetrating keratoplasty (PK) and its impact on graft survival and visual outcome.

DESIGN

Retrospective case series.

PARTICIPANTS

Seven hundred fifteen consecutive eyes of 678 patients undergoing PK.

METHODS

Retrospective review of every case of PK performed at King Khaled Eye Specialist Hospital between January 1, 2001 and December 31, 2002.

MAIN OUTCOME MEASURES

Escalation of glaucoma therapy, graft survival, and visual outcome.

RESULTS

Escalation of glaucoma therapy occurred in 89 (12.4%) eyes of 715 PK procedures during a mean follow-up of 32.2 months. Medical escalation accounted for 73 (82.0%) cases, whereas surgical escalation occurred in 16 (18.0%) eyes. The following were significantly associated with an increased risk of escalation of glaucoma therapy: surgical indication for PK (P<0.001), increasing patient age (P<0.001), preexisting glaucoma (P<0.001), recipient trephination < 7.0 mm (P = 0.02), and pseudophakia or aphakia (P<0.001). Eyes with escalation of glaucoma therapy had significant reduction in graft survival compared with eyes in which this did not occur (52.8% vs. 82.9%, P<0.001). Escalation of glaucoma therapy was associated with a significant reduction in the percentage of eyes achieving visual acuity of 20/40 or better (9.0% vs. 42.1%, P<0.001) and a significant increase in those obtaining 20/200 or worse (70.8% vs. 26.7%, P<0.001).

CONCLUSIONS

Escalation of glaucoma therapy is a serious sequela of PK that is significantly associated with an increased risk of graft failure and poor visual outcome.

摘要

目的

确定穿透性角膜移植术(PK)后青光眼治疗升级的患病率、危险因素及其对移植片存活和视力预后的影响。

设计

回顾性病例系列研究。

研究对象

678例行PK手术患者的715只连续眼。

方法

回顾性分析2001年1月1日至2002年12月31日在沙特国王哈立德眼科专科医院进行的每一例PK手术病例。

主要观察指标

青光眼治疗升级、移植片存活情况和视力预后。

结果

在平均32.2个月的随访期间,715例PK手术中的89只眼(12.4%)出现青光眼治疗升级。药物治疗升级占73例(82.0%),而手术治疗升级发生在16只眼(18.0%)。以下因素与青光眼治疗升级风险增加显著相关:PK的手术指征(P<0.001)、患者年龄增加(P<0.001)、既往青光眼(P<0.001)、受体植孔直径<7.0 mm(P = 0.02)以及人工晶状体眼或无晶状体眼(P<0.001)。与未出现青光眼治疗升级的眼相比,出现青光眼治疗升级的眼的移植片存活率显著降低(52.8%对82.9%,P<0.001)。青光眼治疗升级与视力达到20/40或更好的眼的百分比显著降低相关(9.0%对42.1%,P<0.001),而视力达到20/200或更差的眼的百分比显著增加(70.8%对26.7%,P<0.001)。

结论

青光眼治疗升级是PK的严重后遗症,与移植失败风险增加和视力预后不良显著相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验